TP-122A

Biologic

UUnknown Sponsor

TP-122A is one of 31 biologic programs targeting Ventilator-Associated Pneumonia. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ventilator-Associated PneumoniaActive, not recruiting

Ventilator-Associated PneumoniaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

50 competitors in Ventilator-Associated Pneumonia

#DrugCompanyPhaseTrials

Doribax

Shionogi

Approved

3 2

Merrem

BB. Braun Medical Inc.

Approved

2 3

Vancocin

HHikma Pharmaceuticals LLC

Approved

1 4

Amikin

IInsmed Incorporated

Approved

1 5

Primaxin

Pfizer

Phase 3

1 6

Coly-Mycin M

PParkedale

Phase 3

1 7

Bactrim

UUniversity of California, San Francisco

Phase 3

1 8

Zocor

OOrganon and Co

Phase 3

1 9

Avycaz

PPhiladelphia Eye Associates

Phase 3

1 10

Betadine

BBecton, Dickinson and Company

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Ventilator-Associated Pneumonia1 trial

Phase 1/2a to Assess the Safety and Tolerability of TP-122A for the Treatment of Ventilator-Associated Pneumonia

Not yet recruiting·UUnknown Sponsor·Phase 1/2·NCT06370598·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for TP-122A. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TP-122A compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TP-122A. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Unknown Sponsor company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Company: UUnknown Sponsor

TP-122A

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Ventilator-Associated Pneumonia1 trial

References

Drug Info

Quick Facts

Related News